Your browser doesn't support javascript.
loading
Holmium Laser Enucleation of the Prostate vs Transvesical Single-port Robotic Simple Prostatectomy for Large Prostatic Glands.
Palacios, Diego Aguilar; Kaouk, Jihad; Abou Zeinab, Mahmoud; Ferguson, Ethan L; Abramczyk, Emily; Wright, Henry C; Pramod, Nikhil; De, Smita.
Afiliação
  • Palacios DA; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Kaouk J; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH. Electronic address: kaoukj@ccf.org.
  • Abou Zeinab M; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Ferguson EL; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Abramczyk E; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Wright HC; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH; Northwestern Medicine, Algonquin, IL.
  • Pramod N; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • De S; Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
Urology ; 181: 98-104, 2023 11.
Article em En | MEDLINE | ID: mdl-37517682
ABSTRACT

OBJECTIVE:

To compare the perioperative outcomes of transvesical single-port robotic simple prostatectomy (SP-RASP) and holmium laser enucleation of the prostate (HoLEP). MATERIALS AND

METHODS:

A retrospective review was performed of patients undergoing SP-RASP and HoLEP from 2019 to 2022 with preoperative prostatic volume (PPV) >80 cm3. Percent of prostate adenoma removed (%PAR) was estimated by specimen weight normalized by PPV. Univariate analysis was performed using chi-square, Fisher exact, and Wilcoxon rank-sum tests. A subgroup analysis with 11 matching for PPV was also performed.

RESULTS:

A total of 50 SP-RASP and 90 HoLEP cases were analyzed. The median (interquartile range) PPV was 169 (128-244)cm3 for SP-RASP and 129 (100-150)cm3 for HoLEP, (P < .01). The median (interquartile range) %PAR was 57(44-68) for SP-RASP vs 51(42-62) for HoLEP (P = .10). Overall, 11(12%) HoLEP and 5(10%) SP-RASP patients experienced complications (P = .51). Same-day discharge occurred in 24(48%) SP-RASP vs 7(8%) HoLEP patients (P < .01). Median foley catheter duration was longer in SP-RASP (6 vs 1 day, P < .01) and trial of void was successful at first attempt in >94% (P = .68). Transient de novo incontinence was reported in 24(28%) HoLEP vs 2(5%) SP-RASP (P < .01). No differences in voiding parameters were observed at latest follow up. Subgroup postmatched analysis revealed analogous findings.

CONCLUSION:

SP-RASP and HoLEP have similar favorable perioperative outcomes for management of large prostatic adenomas. SP-RASP may be considered in patients unwilling to accept the risk of transient incontinence and in those with unfavorable urethral access, large bladder stone burden, or diverticula.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Lasers de Estado Sólido / Procedimentos Cirúrgicos Robóticos Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hiperplasia Prostática / Lasers de Estado Sólido / Procedimentos Cirúrgicos Robóticos Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article